378 related articles for article (PubMed ID: 28127506)
41. Peripheral neuropathy in hematologic malignancies - Past, present and future.
Li T; Timmins HC; Lazarus HM; Park SB
Blood Rev; 2020 Sep; 43():100653. PubMed ID: 31983507
[TBL] [Abstract][Full Text] [Related]
42. Burden of chemotherapy-induced neuropathy--a cross-sectional study.
Kautio AL; Haanpää M; Kautiainen H; Kalso E; Saarto T
Support Care Cancer; 2011 Dec; 19(12):1991-6. PubMed ID: 21080201
[TBL] [Abstract][Full Text] [Related]
43. The fundamental role of morphology in experimental neurotoxicology: the example of chemotherapy-induced peripheral neurotoxicity.
Marmiroli P; Nicolini G; Miloso M; Scuteri A; Cavaletti G
Ital J Anat Embryol; 2012; 117(2):75-97. PubMed ID: 23420996
[TBL] [Abstract][Full Text] [Related]
44. [Drug induced neuropathies].
Lagueny A
Rev Prat; 2008 Nov; 58(17):1910-6. PubMed ID: 19157207
[TBL] [Abstract][Full Text] [Related]
45. Rodent models of chemotherapy-induced peripheral neuropathy.
Höke A; Ray M
ILAR J; 2014; 54(3):273-81. PubMed ID: 24615440
[TBL] [Abstract][Full Text] [Related]
46. Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment.
Staff NP; Cavaletti G; Islam B; Lustberg M; Psimaras D; Tamburin S
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2(Suppl 2):S26-S39. PubMed ID: 31647151
[TBL] [Abstract][Full Text] [Related]
47. [Chemotherapy-induced peripheral neuropathy].
Noguchi E; Maeda Y
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1773-6. PubMed ID: 22083183
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
Van Helleputte L; Kater M; Cook DP; Eykens C; Rossaert E; Haeck W; Jaspers T; Geens N; Vanden Berghe P; Gysemans C; Mathieu C; Robberecht W; Van Damme P; Cavaletti G; Jarpe M; Van Den Bosch L
Neurobiol Dis; 2018 Mar; 111():59-69. PubMed ID: 29197621
[TBL] [Abstract][Full Text] [Related]
49. Emerging roles of toll-like receptor 4 in chemotherapy-induced neurotoxicity.
Oo TT; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
Neurotoxicology; 2022 Dec; 93():112-127. PubMed ID: 36152729
[TBL] [Abstract][Full Text] [Related]
50. Challenges Evaluating Chemotherapy-Induced Peripheral Neuropathy in Childhood Cancer Survivors.
Mohrmann C; Armer J; Hayashi RJ
J Pediatr Oncol Nurs; 2017; 34(2):106-114. PubMed ID: 27251891
[TBL] [Abstract][Full Text] [Related]
51. Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability.
Ibañez-Juliá MJ; Berzero G; Reyes-Botero G; Maisonobe T; Lenglet T; Slim M; Louis S; Balaguer A; Sanson M; Le Guern E; Latour P; Ricard D; Stojkovic T; Psimaras D
Acta Oncol; 2018 Mar; 57(3):403-411. PubMed ID: 29243538
[TBL] [Abstract][Full Text] [Related]
52. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Amara S
Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
[TBL] [Abstract][Full Text] [Related]
53. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G
J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066
[TBL] [Abstract][Full Text] [Related]
54. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
[TBL] [Abstract][Full Text] [Related]
55. A Randomized Assessor-Blinded Wait-List-Controlled Trial to Assess the Effectiveness of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy.
Molassiotis A; Suen LKP; Cheng HL; Mok TSK; Lee SCY; Wang CH; Lee P; Leung H; Chan V; Lau TKH; Yeo W
Integr Cancer Ther; 2019; 18():1534735419836501. PubMed ID: 30905173
[TBL] [Abstract][Full Text] [Related]
56. Prevention and therapy of chemotherapy-induced peripheral neuropathy: a review of recent findings.
Michalová Z; Székiová E; Blaško J; Vanický I
Neoplasma; 2023 Feb; 70(1):15-35. PubMed ID: 36573482
[TBL] [Abstract][Full Text] [Related]
57. Chemotherapy-induced peripheral neuropathy.
Visovsky C
Cancer Invest; 2003 Jun; 21(3):439-51. PubMed ID: 12901290
[TBL] [Abstract][Full Text] [Related]
58. Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.
Kerckhove N; Collin A; Condé S; Chaleteix C; Pezet D; Balayssac D
Front Pharmacol; 2017; 8():86. PubMed ID: 28286483
[TBL] [Abstract][Full Text] [Related]
59. Neurotoxicity induced by antineoplastic proteasome inhibitors.
Alé A; Bruna J; Navarro X; Udina E
Neurotoxicology; 2014 Jul; 43():28-35. PubMed ID: 24525285
[TBL] [Abstract][Full Text] [Related]
60. The role of neuromuscular ultrasound in diagnostics of peripheral neuropathies induced by cytostatic agents or immunotherapies.
Hartinger S; Hammersen J; Leistner NA; Lawson McLean A; Risse C; Senft C; Schütze S; Heiling B; Schwab M; Mäurer I
Acta Neuropathol Commun; 2023 Nov; 11(1):187. PubMed ID: 38012771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
